Mirum Pharmaceuticals Stock News

Mirum's maralixibat was approved in September. The company looks like it is executing very well.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals Inc. (NASDAQ:MIRM ) Q1 2022 Results Conference Call May 5, 2022 8:30 AM ET Company Participants Chris Peetz - President, CEO Ian Clements - CFO Peter Radovich - COO Pam Vig - Hea

Mirum Pharmaceuticals, Inc. (MIRM) CEO Chris Peetz on Q4 2021 Results - Earnings Call Transcript

Mirum Pharmaceuticals press release (MIRM): Q4 net income of $57.5MRevenue of $3.14M.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update

Mirum Pharmaceuticals (NASDAQ:MIRM) is scheduled to announce Q4 earnings results on Wednesday, March 9th, after market close.The consensus EPS Estimate is $1.84 and the consensus…

Mirum Pharmaceuticals (MIRM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

During the last session, Mirum Pharmaceuticals Inc. (NASDAQ:MIRM)s traded shares were 0.35 million. At the end of the trading day, the stocks price was $23.12, reflecting an intraday gain of 1.67% or $0.38. The 52-week high for the MIRM share is $23.35, that puts it down -0.99 from that peak though still a striking 44.55% Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) Stock Jumped 29.45% Over A Month Are There Any Chances Of Growth? Read More »

Mirum Pharmaceuticals (MIRM) granted two new employees non-qualified stock options to buy 14.2K common shares and 7.1K restricted stock units under the company''s 2020 Inducement…

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conference

Equities research analysts expect Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) to report ($0.06) earnings per share (EPS) for the current quarter, Zacks reports. Five analysts have provided estimates for Mirum Pharmaceuticals earnings. The lowest EPS estimate is ($2.36) and the highest is $1.66. Mirum Pharmaceuticals reported earnings of ($1.43) per share during the same quarter last year, []

Since Mirum Pharmaceuticals' Livmarli was approved for the treatment of cholestatic pruritus in patients with Alagille syndrome, its stock has fallen some 25%. Although the only approved therapy for A